BAL2420
Multidrug-resistant Gram-negative infections
Phase 1Active (First-in-Human started Mar 2026)
Key Facts
Indication
Multidrug-resistant Gram-negative infections
Phase
Phase 1
Status
Active (First-in-Human started Mar 2026)
Company
About Basilea Pharmaceutica
Basilea Pharmaceutica is a profitable, Swiss-based biopharma company dedicated to becoming a leading global anti-infectives company. Its mission is to address the critical unmet medical need in severe infections through the commercialization of its two marketed products, Cresemba and Zevtera, and the development of a targeted pipeline of novel antibiotics and antifungals. The company's strategy leverages deep expertise in anti-infective development, regulatory navigation, and global commercialization, supported by a disciplined operational focus and strategic partnerships with entities like BARDA.
View full company profileTherapeutic Areas
Other Multidrug-resistant Gram-negative infections Drugs
| Drug | Company | Phase |
|---|---|---|
| Program targeting Enterobacteriaceae | Telum Therapeutics | Pre-clinical |
| Program targeting Acinetobacter baumannii | Telum Therapeutics | Pre-clinical |
| Program targeting Pseudomonas aeruginosa | Telum Therapeutics | Pre-clinical |